Recent advances in adrenal autoimmunity

Area of Science:

• Endocrinology
• Immunology
• Genetics

Background:

• Autoimmune Addison's disease (AAD) is characterized by immune-mediated destruction of adrenocortical cells.
• AAD is a key feature of autoimmune polyendocrine syndromes types 1 and 2 (APS 1 and APS 2).
• Circulating autoantibodies against 21-hydroxylase are hallmarks of the adrenal autoimmune process.

Purpose of the Study:

• To highlight the role of 21-hydroxylase autoantibodies in identifying preclinical Autoimmune Addison's disease.
• To discuss the genetic underpinnings and immune mechanisms involved in AAD pathogenesis.
• To elucidate the progression from preclinical to clinical stages of AAD.

Main Methods:

• Detection of autoantibodies against the steroidogenic enzyme 21-hydroxylase.
• Assessment of adrenocortical function using corticotrophin stimulation tests.
• Analysis of genetic factors, including AIRE gene mutations and HLA associations.
• Investigation of chemokine involvement (e.g., CXCL-10) in immune cell recruitment.

Main Results:

• Detection of 21-hydroxylase autoantibodies identifies individuals with preclinical AAD.
• An impaired corticotrophin stimulation test indicates irreversible preclinical AAD, predicting clinical progression in over 80% of cases.
• APS 1 is linked to AIRE gene mutations, while isolated/APS 2 AAD involves complex genetic susceptibility, notably HLA genes.
• Adrenocortical cells release chemokines like CXCL-10, attracting Th1 cells to the site of autoimmune attack.

Conclusions:

• 21-hydroxylase autoantibodies are crucial biomarkers for early detection of Autoimmune Addison's disease.
• Understanding the genetic and immunological basis of AAD is vital for managing APS 1 and APS 2.
• The progression to clinical AAD is predictable in preclinical stages, offering potential for timely intervention.